Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Moving CAR-T therapy into the frontline setting in myeloma: insights into CARTITUDE-5 & CARTITUDE-6

Michel Delforge, MD, PhD, University of Leuven, Leuven, Belgium, discusses whether CAR-T cells might be integrated into the frontline setting in multiple myeloma. Prof. Delforge gives an overview of clinical trials in this space, including the Phase III CARTITUDE-5 trial (NCT04923893), and the Phase III CARTITUDE-6 trial (NCT05257083), which will challenge the role of autologous stem cell transplantation (autoSCT) in this disease setting. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.